Fenwick & West represented Loxo Oncology, Inc. (NASDAQ: LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, in its $76 million follow-on public offering. The company sold 2,500,000 shares of its common stock at a price to the public of $26.50 per share, including shares sold pursuant to a 30-day option to purchase up to an additional 375,000 shares of its common stock granted to the underwriters.
Citigroup Global Markets Inc. and Cowen and Company, LLC acted as joint book-running managers for the offering. Stifel, Nicolaus & Company, Incorporated acted as joint lead manager, and Oppenheimer & Co. Inc. and Trout Capital LLC acted as co-managers.
The Fenwick transaction team included corporate attorneys Rob Freedman, Horace Nash, Effie Toshav, Julia Forbess, Jordan Roberts and Can Sun.